<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The development of new drugs for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM) and <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> is currently one of the most innovative areas of drug development </plain></SENT>
<SENT sid="1" pm="."><plain>However, a considerable number of newly developed drugs have either not reached the market and were stopped late in development or have been withdrawn after initial approval soon after market authorization due to serious safety concerns </plain></SENT>
<SENT sid="2" pm="?"><plain>How can drug safety problems be anticipated and, even more important, how can adverse events definitely caused by a drug be differentiated from incidences of naturally occurring diseases </plain></SENT>
<SENT sid="3" pm="."><plain>This review article will provide an update about the state of the art treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and reflect on the newest available study evidence on <z:chebi fb="0" ids="50864">glitazones</z:chebi>, incretin mimetics (GLP-1 agonists and DPP-4 inhibitors), SGLT-2 inhibitors (gliflocines) and pan-PPAR <z:chebi fb="4" ids="48705">agonists</z:chebi> (glitazars) </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, new and still experimental approaches for the treatment of T2DM, such as bardoxolone, salsalate and anakinra will be briefly reviewed </plain></SENT>
</text></document>